Whitehawk Therapeutics (WHWK) Short term Debt (2020 - 2021)
Whitehawk Therapeutics' (WHWK) quarterly Short term Debt came in at $258000.0 in Q4 2021, down 98.2% year-on-year from $14.3 million in Q4 2020, and up 1072.73% on a QoQ basis from $22000.0 in Q3 2021.
Whitehawk Therapeutics (WHWK) Short term Debt (2020 - 2021) Analysis & Trends
Whitehawk Therapeutics (WHWK) has 2 years of Short term Debt data on file, last reported at $258000.0 in Q4 2021.
- On a quarterly basis, Short term Debt fell 98.2% year-over-year to $258000.0 in Q4 2021; TTM through Dec 2021 was $258000.0, a 98.2% decrease from a year earlier, with the FY2021 full-year figure at $258000.0, down 98.2% from the prior year.
- Short term Debt for Q4 2021 stood at $258000.0, up from $22000.0 in the prior quarter.
- Over the last five years, Short term Debt for WHWK reached as high as $14.3 million in Q4 2020 and fell as low as $22000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Whitehawk Therapeutics | 260.33 Mn | 49.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 258,000.00 |
| Sep 30, 2021 | 22,000.00 |
| Dec 31, 2020 | 14.31 Mn |